Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Will Work towards Price Maintenance for On-Patent Medicines: New President
May 24, 2021
- Eisai’s Okada Elected as JPMA Chief, Daiichi Sankyo’s Manabe to Head FPMAJ
May 21, 2021
- JPMA Has “Different View” from US Govt on COVID-19 Vaccine IP Waiver
May 10, 2021
- EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
- Regulations for DX, Pre-Symptomatic Disease Up for JPMA Committee Discussion
April 20, 2021
- Asia Trade Groups Discuss Regional Differences in Nonclinical Evaluations of Human Cell Products
April 20, 2021
- JGA Bitterly Reprimands Kobayashi Kako for Application Document Fabrication
April 20, 2021
- Asian Pharma Groups Agree to Ensure Smooth Drug Reviews amid COVID-19 Crisis
April 16, 2021
- Plaintiffs of HPV Vaccine Suits Urge LDP Group to Hear Stories of Sufferers
April 16, 2021
- Scandals Making It Difficult to Recommend Generics to Members: Kyokai Kenpo Chair
April 16, 2021
- Govt Should Set API-by-API Targets for Biosimilars: Society Chief
April 15, 2021
- Hold Off on Nichi-Iko Products for Now to Remove Generic Distrust: Pharmacy Chief
April 9, 2021
- Wakayama Council Makes List of 500 Drugs Commonly Used in Region, Snubs Nichi-Iko/Kobayashi Kako Generics
April 9, 2021
- Industry Group Rolls Out Barcode Reader App for E-Labeling
April 8, 2021
- Generic Industry Group Requests Blanket Manufacturing Checkups for 39 Member Firms
March 31, 2021
- 27.2% Pharmacists Want Total Product Switch from Nichi-Iko to Other Makers, 56.6% Hoping Partial Switch: Survey
March 31, 2021
- Generic Use Rate at 79.4% in October-December 2020: JGA
March 29, 2021
- Industry Group Poised for Pilot Rollout of E-Labeling App in April, Looks to Sales Reps for Popularization
March 26, 2021
- JPMA Renews Call for Post-Launch Innovation Review in 2021 Proposal
March 24, 2021
- Japan Govt Should Change Course on Consistent Price Cuts for On-Patent Drugs: FPMAJ Exec
March 22, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…